VERAVera Therapeutics, Inc.

$36.81

$19.7952 weeks$55.67

Price

$36.81+87%1Y

1M+1.3%1Y+87%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Below average

4/10

Value36

Quality32

Momentum78

Growth-

Strongest Momentum, weakest Quality · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

We are a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Our lead product candidate, atacicept, is currently being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. Atacicept is a native human TACI-Fc fusion protein that binds both the B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) cytokines and is self-administered subcutaneously at home.

In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR

P/E (TTM)-

Market Cap$2.52B

1Y Return+87%

5Y Return+112%